Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

3.360 +0.740 (+28.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
BayMedica LLC: Working With Cannabis Multi-State Operators To Make Their Products Better
InMed Pharmaceuticals Inc. (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is taking a leading position in the marketplace. 
Via Benzinga
Marijuana As An Appetite Suppressant? It's A Possibility
Using cannabis as an appetite suppressant for weight management may seem counterintuitive, but one rare cannabinoid may have just that effect. Delta-9 (d-9)-dominant tetrahydrocannabivarin (THCV) has... 
Via Benzinga
InMed Pharmaceuticals: The Clinical-Stage Company Setting Sites On Dominating Rare Cannabinoid Production And Commercialization Across Global Markets
Shane Johnson, SVP and General Manager of Baymedica of InMed Pharmaceuticals (NASDAQ: INM), was a guest speaker at Benzinga’s All Access on June 17th, 2022. 
Via Benzinga
InMed Publishes Study On Potential Role Of Rare Cannabinoids For Skin Conditions
InMed Pharmaceuticals Inc. (NASDAQ: INM) announced that a peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been... 
Via Benzinga
InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings
InMed Pharmaceuticals Inc. (NASDAQ: INM) has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4.08 million of its common... 
Via Benzinga
InMed Pharmaceuticals' Issues Annual Shareholder Letter
InMed Pharmaceuticals (NASDAQ: 
Via Benzinga
InMed Pharmaceuticals Is Commercializing The Development Of Rare Cannabinoids For The Wellness Market
Upon its acquisition of BayMedica LLC last year, InMed Pharmaceuticals Inc. (Nasdaq: INM) made the executive decision to forge a new path alongside its traditional domain in pharmaceutical drug... 
Via Benzinga
InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition
InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the... 
Via Benzinga
InMed Commercializes Rare Cannabinoids For Health And Wellness Market
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers for today as we prepare for a busy day of trading on Tuesday! 
Via InvestorPlace
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and MicroSafe Group DMCC reported EPA approval for... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:... 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Announces Expansion Of Rare Cannabinoid Portfolio
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
InMed Pharmaceuticals (NASDAQ: INM) Announces Participation In Upcoming Conferences
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
InMed Pharmaceuticals Committed To Growing Market Reach, Product Portfolio
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.   
Via Benzinga
InMed Pharmaceuticals Makes Changes In Management
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... 
Via Benzinga
InMed Launching Additional Rare Cannabinoids In Response To Demand
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
InMed Pharmaceuticals Expanding Portfolio In Rare Cannabinoid Market
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
InMed's Evolution To Commercial Sales Featured In Research Report
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
InMed Names BayMedica VP Of Sales, Releases Q2 2022 Report
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
InMed Positioned To Offer Rare Cannabinoid Manufacturing Technologies
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
InMed Pharmaceuticals To Release Q2 Financial Report, Update
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
InMed Pharmaceuticals Strengthens Leading Role In Rare Cannabinoid Market
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cannabicitran is the first of four new rare cannabinoids InMed... 
Via Benzinga
InMed Pharmaceuticals Defining Value Of Rare Cannabinoids In Pharma Space
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
InMed Pharmaceuticals Expands Rare Cannabinoid Product Portfolio to Launch CBT
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... 
Via Benzinga
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... 
Via Benzinga
InMed Pharmaceuticals to Present at Tribe Public's Webinar Event
InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.